Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 5, 2011, Pages 1081-1088

  Cardone, Katie E ^a,b   Lodise, Thomas P ^a,c   Patel, Nimish ^a   Hoy, Christopher D ^d   Meola, Shari ^d   Manley, Harold J ^e   Drusano, George L ^c   Grabe, Darren W ^a,b,f  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Albany Nephrology Pharmacy ANephRx Group   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d Hortense and Louis Rubin Dialysis Center   (United States)

^e Village Health Disease Management   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN;

ADULT; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; ENDOCARDITIS; FEMALE; HUMAN; MALE; MONTE CARLO METHOD; PERITONEAL CAVITY; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PERITONEAL CAVITY; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; STAPHYLOCOCCAL INFECTIONS;

EID: 79957803618     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08510910     Document Type: Article

References (29)

1. Fuchs PC, Barry AL, Brown SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 45: 1915-1918, 2001
2. Wong SS, Ho PL, Yuen KY: Evolution of antibiotic resistance mechanisms and their relevance to dialysis-related infections. Perit Dial Int 27[Suppl 2]: S272-S280, 2007
3. Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, Vas SI, Oreopoulos DG: Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 22: 573-581, 2002
4. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49: 507-514, 2009
5. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320, 2008
6. Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: 1330-1336, 2008
7. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98, 2009
8. Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Haller H, Fliser D, Kielstein JT: Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 24: 267-271, 2009
9. Carpenter CF, Chambers HF: Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38: 994-1000, 2004
10. Goedecke VA, Clajus C, Burkhardt O, Martens-Lobenhoffer J, Bode-Boger SM, Kielstein JT, Hiss M: Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scand J Infect Dis 41: 155-157, 2009
11. Khadzhynov D, Joukhadar C, Peters H: Plasma and peritoneal dialysate levels during daptomycin therapy for peritonitis. Am J Kidney Dis 53: 911-912, 2009
12. Leary R, Jelliffe R, Schumitzky A, van Guilder M: An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. Proceedings, Fourteenth IEEE Symposium on Computer-Based Medical Systems. Bethesda MD, IEEE Computer Society, 2001
13. Janicke DM, Morse GD, Apicella MA, Jusko WJ, Walshe JJ: Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther 40: 209-218, 1986
14. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9: 115-134, 1979
15. Bowker KE, Noel AR, MacGowan AP: Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother 64: 1044-1051, 2009
16. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP: Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52: 405-411, 2003
17. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45: 845-851, 2001
18. Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48: 63-68, 2004
19. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL: Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50: 1568-1574, 2010
20. Eisenstein BI, Oleson FB, Jr. & Baltz RH: Daptomycin: From the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 50[Suppl 1]: S10-S15, 2010
21. Oleson FB, Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44: 2948-2953, 2000
22. Lodise TP, Lomaestro BM, Drusano GL: Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the Society ofInfectious Diseases Pharmacists. Pharmacotherapy 26: 1320-1332, 2006
23. Patel N, Pallotta K, Grabe DW, Meola S, Hoy C, Drusano GL, Lodise TP: Daptomycin (D) Pharmacokinetics (PK) in Patients Receiving Standardized 3X Weekly Hemodialysis (HD) [Abstract A1-1274]. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2009
24. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA: Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 4: 1190-1194, 2009
25. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA: Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 25: 1279-1284, 2010
26. Traunmuller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagl E, Joukhadar C: Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65: 1252-1257, 2010
27. Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Boger SM, Hiss M, Kielstein JT: Therapeutic serum concentrations of daptomycin after intraperitoneal administration in a patient with peritoneal dialysis-associated peritonitis. J Antimicrob Chemother 65: 1312-1314, 2010
28. Hassoun AA, Coomer RW, Mendez-Vigo L: Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis. Perit Dial Int 29: 671-673, 2009
29. Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK: Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 54: 538-541, 2009